Mentions
Extended reach
Total likes
Video views
AI synopsis
The analysis reflects a generally neutral stance with interest sparked by novel implications like neuroinflammation and blood-brain barrier stability, exemplified by comments on potential new uses beyond diabetes. The tone varies from informative to speculative, showing some engagement but limited in-depth debate, which aligns with moderate scores across the dimensions.
The discussions show mixed reactions; some posts acknowledge the article and its insights, while others are more neutral or focus on related topics.
Most posts demonstrate moderate curiosity, especially when mentioning potential new applications of GLP-1 receptor agonists like treatment for Alzheimer’s disease, indicating some level of engagement with the subject.
Posts reference specific details, such as mechanisms of action and clinical relevance, suggesting a moderate level of active participation and consideration.
Overall, the discussions indicate that the article influences some thinking and awareness but does not appear to significantly shift opinions or drive widespread change.
@isidoro_cano @mbotana @DiegoBellido2 @cristinatejerap @moreno_perez_o @mdballesteros @fjavesc @irenecabmat @estebanjodar @RosaCasan @DrPMiramontes @DrTinahones GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art https://t.co/URfG0bXxpf Gracias @isidoro_cano https://t.co/bmTVWwzHfS
GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of... https://t.co/7pOvarGwzw
1- Very informative interview of Lotte Bjerre Knudsen, including the potential role for GLP-1 receptor agonists in the treatment of Alzheimer's disease. She hypothesizes that the mechanisms of action could be ⬇️neuroinflammation & ⬆️stability of blood-brain barrier. #medsky #geronsky
GLP-1 receptor agonists in the treatment of type 2 diabetes 013 state-of-the-art https://t.co/RZMxIhyapg
GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of... https://t.co/ez1XlYFx5p
RT @CristobMorales: @isidoro_cano @mbotana @DiegoBellido2 @cristinatejerap @moreno_perez_o @mdballesteros @fjavesc @irenecabmat @estebanjod…
Explore the science of fat loss with Nicolas Verhoeven from Physionic. This video discusses exercise's impact on weight loss and body composition, addressing insulin regulation and common misconceptions. Discover…
Berberine, a natural compound, has been shown to improve insulin sensitivity and hormonal balance in women with PCOS undergoing IVF, with effects comparable to metformin. A clinical study found that berberine increased…
This video reviews the mechanism of action of GLP1 receptor agonists in type 2 diabetes, focusing on their role in regulating blood sugar, insulin secretion, and appetite through hormonal and neural pathways, as…
This video discusses the mechanisms, pros, and cons of the popular GLP weight loss peptides Semaglutide, Tirzepatide, and Retatrutide, including personal research results and peptide regimens for weight management.
Joseph shares his personal peptide stacks dosages, which helped him lose over 35 pounds, gain muscle, and reduce blood triglycerides by 100 points in 4 months at age 52. He also discusses research on the new weight loss…
GLP-1 receptor agonists are key medications for type 2 diabetes, boosting insulin, reducing appetite, and aiding weight loss. This video covers their evolution from early forms to long-acting options, highlighting their…
@ThomasSexton_AU 5/5 com/pmj/article-abstract/96/1133/156/6842784 - [GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art]https://www sciencedirect.
1- Very informative interview of Lotte Bjerre Knudsen, including the potential role for GLP-1 receptor agonists in the treatment of Alzheimer's disease. She hypothesizes that the mechanisms of action could be ⬇️neuroinflammation & ⬆️stability of blood-brain barrier. #medsky #geronsky
GLP-1 receptor agonists in the treatment of type 2 diabetes 013 state-of-the-art https://t.co/RZMxIhyapg
GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of... https://t.co/ez1XlYFx5p
RT @cristinatejerap: GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of... https://t.co/7pOvarGwzw
GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of... https://t.co/7pOvarGwzw
RT @CristobMorales: @isidoro_cano @mbotana @DiegoBellido2 @cristinatejerap @moreno_perez_o @mdballesteros @fjavesc @irenecabmat @estebanjod…
RT @CristobMorales: @isidoro_cano @mbotana @DiegoBellido2 @cristinatejerap @moreno_perez_o @mdballesteros @fjavesc @irenecabmat @estebanjod…
RT @CristobMorales: @isidoro_cano @mbotana @DiegoBellido2 @cristinatejerap @moreno_perez_o @mdballesteros @fjavesc @irenecabmat @estebanjod…
RT @CristobMorales: @isidoro_cano @mbotana @DiegoBellido2 @cristinatejerap @moreno_perez_o @mdballesteros @fjavesc @irenecabmat @estebanjod…
RT @CristobMorales: @isidoro_cano @mbotana @DiegoBellido2 @cristinatejerap @moreno_perez_o @mdballesteros @fjavesc @irenecabmat @estebanjod…
RT @CristobMorales: @isidoro_cano @mbotana @DiegoBellido2 @cristinatejerap @moreno_perez_o @mdballesteros @fjavesc @irenecabmat @estebanjod…
@isidoro_cano @mbotana @DiegoBellido2 @cristinatejerap @moreno_perez_o @mdballesteros @fjavesc @irenecabmat @estebanjodar @RosaCasan @DrPMiramontes @DrTinahones GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art https://t.co/URfG0bXxpf Gracias @isidoro_cano https://t.co/bmTVWwzHfS